Ocular Therapeutix Achieves 555 Subject Randomization Target in SOL-R Trial for Wet AMD Treatment

Ocular Therapeutix has achieved the target randomization of 555 subjects in its SOL-R registrational trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The trial, which aims to demonstrate non-inferiority in visual acuity from baseline at Week 56, remains on track for topline data in 1H 2027. Ocular plans to submit a new drug application (NDA) for AXPAXLI in wet AMD based on the data from SOL-R and its complementary trial, SOL-1.